Immunotherapy of rheumatoid arthritis using CD4⁺CD25⁺ regulatory T cells

Appelboom T, Halberg B (2004) Rheumatoid arthritis and other synovial disorders. In: MC Hochberg, AJ Silman, JS Smolen, ME Weinblatt, MH Weisman (eds): Rheumatology, 3rd ed., Mosby, London, 753–937Google Scholar

Hochberg MC, Spector TD (1990) Epidemiology of rheumatoid arthritis: update. Epidemiol Rev 12: 247–252PubMedGoogle Scholar

Hochberg MC (1983) Epidemiology of rheumatoid arthritis in developed countries. J Rheumatol (Suppl) 10: 7–10Google Scholar

Silman AJ, Pearson JE (2002) Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 4(Suppl 3): S265–S272PubMedGoogle Scholar

Jarvinen P, Aho K (1994) Twin studies in rheumatic diseases. Semin Arthritis Rheum 1:19–28Google Scholar

Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ (1993) Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 261:1328–1330PubMedGoogle Scholar

Kim WU, Cho ML, Jung YO, Min SY, Park SW, Min DJ, Yoon JH, Kim HY (2004) Type II collagen autoimmunity in rheumatoid arthritis. Am J Med Sci 4: 202–211Google Scholar

Cook AD, Rowley MJ, Mackay IR, Gough A, Emery P (1996) Antibodies to type II collagen in early rheumatoid arthritis. Correlation with disease progression. Arthritis Rheum 10: 1720–1727Google Scholar

van Eden W (1991) Heat-shock proteins as immunogenic bacterial antigens with the potential to induce and regulate autoimmune arthritis. Immunol Rev 121: 5–28PubMedGoogle Scholar

McDevitt H (2000) A new model for rheumatoid arthritis? Arthritis Res 2: 85–89PubMedGoogle Scholar

Verheijden GF, Rijnders AW, Bos E, Coenen-de Roo CJ, van Staveren CJ, Miltenburg AM, Meijerink JH, Elewaut D, de Keyser F, Veys E et al (1997) Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum 6:1115–1125Google Scholar

Corrigall VM, Bodman-Smith MD, Fife MS, Canas B, Myers LK, Wooley P, Soh C, Staines NA, Pappin DJ, Berlo SE et al (2001) The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J Immunol 3: 1492–1498Google Scholar

Myers LK, Rosloniec EF, Cremer MA, Kang AH (1997) Collagen-induced arthritis, an animal model of autoimmunity. Life Sci 19: 1861–1878Google Scholar

Luross JA, Williams NA (2001) The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 4: 407–416Google Scholar

Holoshitz J, Matitiau A, Cohen IR (1985) Role of the thymus in induction and transfer of vaccination against adjuvant arthritis with a T lymphocyte line in rats. J Clin Invest 2: 472–477Google Scholar

Cush JJ, Lipsky PE (1988) Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. Arthritis Rheum 10:1230–1238Google Scholar

Kidd P (2003) Thl/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 3: 223–246Google Scholar

van Roon JA, Bijlsma JW, Lafeber FP (2002) Suppression of inflammation and joint destruction in rheumatoid arthritis may require a concerted action of Th2 cytokines. Curr Opin Invest Drugs 7: 1011–1016Google Scholar

Salmon M, Scheel-Toellner D, Huissoon AP, Pilling D, Shamsadeen N, Hyde H, D’Angeac AD, Bacon PA, Emery P, Akbar AN (1997) Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest 3: 439–446Google Scholar

Buckley CD, Amft N, Bradfield PF, Pilling D, Ross E, Arenzana-Seisdedos F, Amara A, Curnow SJ, Lord JM, Scheel-Toellner D et al (2000) Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol 6: 3423–3429Google Scholar

lannone F, Corrigal VM, Panayi GS (1996) CD69 on synovial T cells in rheumatoid arthritis correlates with disease activity. Br J Rheumatol 35: 397PubMedGoogle Scholar

Liu MF, Chao SC, Wang CR, Lei HY (2001) Expression of CD40 and CD40 ligand among cell populations within rheumatoid synovial compartment. Autoimmunity 2:107–113Google Scholar

Pacholczyk R, Kraj P, Ignatowicz L (2002) Peptide specificity of thymic selection of CD4⁺CD25⁺ T cells. J Immunol 2: 613–620Google Scholar

MacDonald KP, Nishioka Y, Lipsky PE, Thomas R (1997) Functional CD40 ligand is expressed by T cells in rheumatoid arthritis. J Clin Invest 9: 2404–2414Google Scholar

Ranges GE, Sriram S, Cooper SM (1985) Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med 3: 1105–1110Google Scholar

Levitt NG, Fernandez-Madrid F, Wooley PH (1992) Pristane induced arthritis in mice. IV. Immunotherapy with monoclonal antibodies directed against lymphocyte subsets. J Rheumatol 9: 1342–1347Google Scholar

Van den Broek MF, Van de Langerijt LG, Van Bruggen MC, Billingham ME, Van den Berg WB (1992) Treatment of rats with monoclonal anti-CD4 induces long-term resistance to streptococcal cell wall-induced arthritis. Eur J Immunol 1: 57–61Google Scholar

Pohlers D, Nissler K, Frey O, Simon J, Petrow PK, Kinne RW, Brauer R (2004) Anti-CD4 monoclonal antibody treatment in acute and early chronic antigen-induced arthritis: influence on T helper cell activation. Clin Exp Immunol 3: 409–415Google Scholar

Moreland LW, Pratt PW, Mayes MD, Postlethwaite A, Weisman MH, Schnitzer T, Light-foot R, Calabrese L, Zelinger DJ, Woody JN (1995) Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 11:1581–1588Google Scholar

van der Lubbe PA, Dijkmans BA, Markusse HM, Nassander U, Breedveld FC (1995) A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 8: 1097–1106Google Scholar

Choy EH, Panayi GS, Emery P, Madden S, Breedveld FC, Kraan MC, Kalden JR, Rascu A, Brown JC, Rapson N, Johnston JM (2002) Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology (Oxford) 10: 1142–1148Google Scholar

Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF et al (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 20:1907–1915Google Scholar

Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, Cohen S, Luggen M, Shergy W, Nuamah I et al (2002) Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 6: 1470–1479Google Scholar

Kim HJ, Berek C (2000) B cells in rheumatoid arthritis. Arthritis Res 2: 126–131PubMedGoogle Scholar

Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 25: 2572–2581Google Scholar

Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester GR (2000) Macrophages in rheumatoid arthritis. Arthritis Res 3: 189–202Google Scholar

Mulherin D, Fitzgerald O, Bresnihan B (1996) Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1: 115–124Google Scholar

van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, Booma-Frankfort C, van der Veen MJ, Haanen HC, Hofman DM, Albada-Kuipers GA, ter Borg EJ et al. (1996) The effectiveness of early treatment with “second-line” antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 8: 699–707Google Scholar

Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, Verburg KM, Isakson PC, Hubbard RC, Geis GS (1999) Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 354: 2106–2111PubMedGoogle Scholar

Bijlsma JW, Van Everdingen AA, Huisman M, De Nijs RN, Jacobs JW (2002) Glucocorticoids in rheumatoid arthritis: effects on erosions and bone. Ann NY Acad Sci 966:82–90PubMedGoogle Scholar

Lundberg IE, Grundtman C, Larsson E, Klareskog L (2004) Corticosteroids — from an idea to clinical use. Best Pract Res Clin Rheumatol 1: 7–19Google Scholar

Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I, Wolfe F (2002) Evidence from clinical trials and long-term observational studies that disease-modifying antirheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology 12: 1346–1356Google Scholar

Breedveld FC, Kalden JR (2004) Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis 6: 627–633Google Scholar

Chan ES, Cronstein BN (2002) Molecular action of methotrexate in inflammatory diseases. Arthritis Res 4: 266–273PubMedGoogle Scholar

Cronstein BN (1995) The antirheumatic agents sulphasalazine and methotrexate share an anti-inflammatory mechanism. Br J Rheumatol 34(Suppl 2): 30–32PubMedGoogle Scholar

Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19: 163–196PubMedGoogle Scholar

Feldmann M, Brennan FM, Williams RO, Woody JN, Maini RN (2004) The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol 1: 59–80Google Scholar

Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 6: 1761–1769Google Scholar

Taylor PC (2003) Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol 3:323–328PubMedGoogle Scholar

Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 3:1151–1164Google Scholar

Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN (2001) Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol 4: 1122–1131Google Scholar

Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi S (1999) Thymus and autoimmunity: production of CD25⁺CD4⁺ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 9: 5317–5326Google Scholar

Stephens LA, Mottet C, Mason D, Powrie F (2001) Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol 4:1247–1254Google Scholar

Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH (2002) Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 9: 4272–4276Google Scholar

Mottet C, Uhlig HH, Powrie F (2003) Cutting edge: cure of colitis by CD4(+)CD25(+) regulatory T cells. J Immunol 8: 3939–3943Google Scholar

Cavani A, Nasorri F, Ottaviani C, Sebastiani S, De Pita O, Girolomoni G (2003) Human CD25⁺ regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals. J Immunol 11: 5760–5768Google Scholar

Suri-Payer E, Amar AZ, Thornton AM, Shevach EM (1998) CD4⁺CD25⁺ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 3: 1212–1218Google Scholar

Shevach EM (2001) Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 11: F41–F46Google Scholar

Piccirillo CA, Shevach EM (2001) Cutting edge: control of CD8⁺ T cell activation by CD4⁺CD25⁺ immunoregulatory cells. J Immunol 3: 1137–1140Google Scholar

Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, Shimizu J, Sakaguchi S (1998) Immunologic self-tolerance maintained by CD25⁺CD4⁺ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 12: 1969–1980Google Scholar

Read S, Malmstrom V, Powrie F (2000) Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2: 295–302Google Scholar

Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S (2002) Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2: 135–142Google Scholar

McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, Byrne MC (2002) CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2: 311–323Google Scholar

Hara M, Kingsley CI, Niimi M, Read S, Turvey SE, Bushell AR, Morris PJ, Powrie F, Wood KJ (2001) IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 6: 3789–3796Google Scholar

Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, Nawata H, Strober W (2004) TGF-betal plays an important role in the mechanism of CD4⁺CD25⁺ regulatory T cell activity in both humans and mice. J Immunol 2: 834–842Google Scholar

Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM (2003) Conversion of peripheral CD4⁺. J Exp Med 12: 1875–1886Google Scholar

Zheng SG, Gray JD, Ohtsuka K, Yamagiwa S, Horwitz DA (2002) Generation ex vivo of TGF-beta-producing regulatory T cells from CD4⁺CD25-precursors. J Immunol 8:4183–4189Google Scholar

Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057–1061PubMedGoogle Scholar

Cederbom L, Hall H, Ivars F (2000) CD4⁺CD25⁺ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 6: 1538–1543Google Scholar

Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV (2004) Cutting Edge: Human CD4⁺CD25⁺ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 8: 4676–4680Google Scholar

Bardos T, Czipri M, Vermes C, Finnegan A, Mikecz K, Zhang J (2003) CD4⁺CD25⁺ immunoregulatory T cells may not be involved in controlling autoimmune arthritis. Arthritis Res Ther 2: R106–R113Google Scholar

Morgan ME, Sutmuller RP, Witteveen HJ, Van Duivenvoorde LM, Zanelli E, Melief CJ, Snijders A, Offringa R, De Vries RR, Toes RE (2003) CD25⁺ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum 5:1452–1460Google Scholar

Cao D, Malmstrom V, Baecher-Allan C, Hafler D, Klareskog L, Trollmo C (2003) Isolation and functional characterization of regulatory CD25^brightCD4⁺ T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol 1: 215–223Google Scholar

van Amelsfort J, Jacobs K, Bijlsma JW, Lafeber FP, Taams L (2004) CD4⁺CD25⁺ regulatory T cells in rheumatoid arthritis: differences in presence, phenotype and function between peripheral blood and synovial fluid. Arthritis Rheum 50: 2775–2785PubMedGoogle Scholar

Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA (2001) CD4⁺CD25high regulatory cells in human peripheral blood. J Immunol 3: 1245–1253Google Scholar

de Kleer IM, Wedderburn LR, Taams LS, Patel A, Varsani H, Klein M, de Jager W, Pugayung G, Giannoni F, Rijkers G et al (2004) CD4⁺CD25(bright) regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 10: 6435–6443Google Scholar

Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S (2000) Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2: 303–310Google Scholar

Baecher-Allan C, Viglietta V, Hafler DA (2002) Inhibition of human CD4(+) CD25(+high) regulatory T cell function. J Immunol 11: 6210–6217Google Scholar

Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G (2001) Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 11: 1303–1310Google Scholar

Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH (2001) Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 11: 1285–1294Google Scholar

van Roon JA, Glaudemans KA, Bijlsma JW, Lafeber FP (2003) Interleukin 7 stimulates tumour necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid arthritis. Ann Rheum Dis 2: 113–119Google Scholar

Dolhain RJ, Ter Haar NT, De Kuiper R, Nieuwenhuis IG, Zwinderman AH, Breedveld FC, Miltenburg AM (1998) Distribution of T cells and signs of T-cell activation in the rheumatoid joint: implications for semiquantitative comparative histology. Br J Rheumatol 3: 324–330Google Scholar

Cao D, Vollenhoven RR, Klareskog L, Trollmo C, Malmstrom V (2004) CD25^brightCD4⁺ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther 4: R335–R346Google Scholar

Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C (2004) Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF{alpha} therapy. J Exp Med 3: 277–285Google Scholar

Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G (2002) Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med 2: 247–253Google Scholar

Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH (2002) Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med 2: 255–260Google Scholar

Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, Masteller EL, McDevitt H, Bonyadi M, Bluestone JA (2004) In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 11: 1455–1465Google Scholar

Yamazaki S, Iyoda T, Tarbell K, Olson K, Velinzon K, Inaba K, Steinman RM (2003) Direct expansion of functional CD25⁺ CD4⁺ regulatory T cells by antigen-processing dendritic cells. J Exp Med 2: 235–247Google Scholar

Yamagiwa S, Gray JD, Hashimoto S, Horwitz DA (2001) A role for TGF-beta in the generation and expansion of CD4⁺CD25⁺ regulatory T cells from human peripheral blood. J Immunol 12: 7282–7289Google Scholar

Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF (2004) Cutting edge: TGF-beta induces a regulatory phenotype in CD4⁺. J Immunol 9: 5149–5153Google Scholar

Lin CH, Hiinig T (2003) Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol 3: 626–638Google Scholar

Prakken BJ, Samodal R, Le TD, Giannoni F, Yung GP, Scavulli J, Amox D, Roord S, de Kleer I, Bonnin D et al. (2004) Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci USA 12:4228–4233Google Scholar

Horwitz DA, Zheng SG, Gray JD, Wang JH, Ohtsuka K, Yamagiwa S (2004) Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease. Semin Immunol 2: 135–143Google Scholar

Qin S, Cobbold SP, Pope H, Elliott J, Kioussis D, Davies J, Waldmann H (1993) “Infectious” transplantation tolerance. Science 259: 974–977PubMedGoogle Scholar